TRP_1170x120_3-8-19

Hyrimoz (adalimumab-adaz)

Sandoz receives U.S. FDA approval for biosimilar Hyrimoz

Sandoz receives U.S. FDA approval for biosimilar Hyrimoz

HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s